^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
DC vaccine for prostate cancer
i
Other names: DC vaccine for prostate cancer, mRNA-transfected dendritic cell vaccine, dendritic cell vaccine
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Medigene, Oslo University Hospital
Drug class:
NK cell stimulant
Related drugs:
1year
WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy. (PubMed, Leukemia)
Oral azacytidine may be used as maintenance treatment in AML in first remission, but can be associated with substantial side effects, and less toxic strategies should be explored. OS at five years was 75% (95% CI: 50-89), with 70% of patients ≥60 years of age being long-term survivors. Maintenance therapy with this DC vaccine was well tolerated in AML patients in CR1 and was accompanied by encouraging 5-year long-term survival.
Journal
|
PRAME (Preferentially Expressed Antigen In Melanoma)
|
azacitidine • CVT-DC-01 • DC vaccine for prostate cancer
Share via
